The JN.1 sub-variant is a new variant of the SARS-CoV-2 Omicron strain, derived from the BA.2.86 sub-variant. It was first detected in late 2023 and has quickly spread to many countries, becoming the most prevalent variant in some regions. JN.1 exhibits a unique mutation (L455S) in the spike protein compared to the BA.2.86 lineage, which may affect its transmissibility and immune evasion capabilities. JN.1 has been designated as a “variant of interest” by the World Health Organization due to its rapidly increasing spread and is being closely monitored for its impact on the COVID-19 pandemic. This study describes the emergence of SARS-CoV-2 JN.1 sub-variant in Tunisia, and reports its mutation profiles.
Nasopharyngeal samples collected over a four-month period (October 2023 to January 2024) were subjected to RNA extraction and real-time RT-PCR confirmation of SARS-CoV-2 infection. The whole-genome sequencing was performed by an iSeq 100 sequencer and COVIDSeq kit reagents (Illumina, USA).
Mutation analysis, using the NextClade platform and GISAID database, revealed the presence of JN.1 in 15 out of 80 positive cases (18.75%) during the study period.
The emergence of JN.1 highlights the ongoing evolution of SARS-CoV-2 and the need for continued surveillance and research to better understand the characteristics and impact of emerging variants.
Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy 2020; 5: 6. https://doi.org/10.1186/s41256-020-00135-6.
Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19 Genomics UK Consortium, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 2023. https://doi.org/10.1038/s41579-022-00841-7.
Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 Omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses 2023; 15: 167. https://doi.org/10.3390/v15010167.
Update on SARS-CoV-2 variant JN.1 being tracked by CDC. Centers for Disease Control and Prevention; 2023. https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html.
COVID-19 epidemiological update – 22 December 2023. World Health Organization (WHO); 2023. https://www.who.int/publications/m/item/covid-19-epidemiological-update–22-december-2023.
Rubin R. As COVID-19 cases surge, here’s what to know about JN.1, the latest SARS-CoV-2 “variant of interest,”. JAMA 2024. https://doi.org/10.1001/jama.2023.27841.
Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022; 603: 679–686. https://doi.org/10.1038/s41586-022-04411-y.
Pather S, Madhi SA, Cowling BJ, Moss P, Kamil JP, Ciesek S, et al. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front Immunol 2023; 14: 1130539. https://doi.org/10.3389/fimmu.2023.1130539.
Quarleri J, Delpino MV, Galvan V. Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN.1 and its projected impact on older adults. GeroScience 2024. s11357-024-01066–7. https://doi.org/10.1007/s11357-024-01066-7.
Altamimi I, Alabdulkarim IM, Alhumimidi AS, Albabtain MA, Temsah M-H. Navigating novel uncertainties of COVID-19: the rise of the JN.1 variant. Cureus 2024. https://doi.org/10.7759/cureus.51497.
Khan SA, Bhuiyan MA, Dewan SMR. JN.1: The present public health concern pertains to the emergence of a novel variant of COVID-19. Environ Health Insights 2024; 18: 11786302241228958. https://doi.org/10.1177/11786302241228958.
Bartel A, Grau JH, Bitzegeio J, Werber D, Linzner N, Schumacher V, et al. Timely monitoring of SARS-CoV-2 RNA fragments in wastewater shows the emergence of JN.1 (BA.2.86.1.1, clade 23I) in Berlin, Germany. Viruses 2024; 16: 102. https://doi.org/10.3390/v16010102.
Hamzaoui Z, Ferjani S, Medini I, Charaa L, Landolsi I, Ben Ali R, et al. Genomic surveillance of SARS-CoV-2 in North Africa: 4 years of GISAID data sharing. IJID Regions 2024;100356. Available from: https://doi.org/10.1016/j.ijregi.2024.100356.
Fang L, Xu J, Zhao Y, Fan J, Shen J, Liu W, et al. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. Front Microbiol 2023; 14: 1228128. https://doi.org/10.3389/fmicb.2023.1228128.
Focosi D, Spezia PG, Gueli F, Maggi F. The Era of the FLips: how spike mutations L455F and F456L (and A475V) are shaping SARS-CoV-2 evolution. Viruses 2023; 16: 3. https://doi.org/10.3390/v16010003.
Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Microbiology 2023. https://doi.org/10.1101/2023.12.08.570782.